Search results
Results from the WOW.Com Content Network
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
By Mariam Sunny and Kamal Choudhury (Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly ...
Clinical trial number NCT04136184 for "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" at ClinicalTrials.gov
IONIS Education Group; IONIS School of Technology and Management; Ionis Pharmaceuticals This page was last edited on 30 September 2018, at 19:02 (UTC). Text is ...
C. Frank Bennett is an American pharmacologist.Bennett is currently the Senior Vice President of Research and Neurology Franchise Leader at Ionis Pharmaceuticals. [1] He is a 2019 Breakthrough Prize winner in Life Sciences, which he shared with his collaborator Adrian R. Krainer for the development of an effective antisense oligonucleotide therapy for children with the neurodegenerative ...
IONIS Education Group is a private, for-profit, higher education group in France. [6] It was created in 1980 [ 7 ] and by 2023 had more than 35,000 students and 100,000 alumni. [ 8 ] There are 29 further education colleges in the group.
Nusinersen, [7] marketed as Spinraza, [4] is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. [8] [4] In December 2016, it became the first approved drug used in treating this disorder.
Evazarsen sodium (IONIS-AGT-LRx) is an antisense RNA designed to inhibit angiotensinogen as an alternative to other mechanisms to target the renin–angiotensin–aldosterone system. [ 1 ] [ 2 ] [ 3 ]